Stock NTLA INTELLIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Delayed Nasdaq
Other stock markets
 03:55:15 2024-04-29 pm EDT 		5-day change 1st Jan Change
21.95 USD +5.75% Intraday chart for Intellia Therapeutics, Inc. +0.60% -27.98%
Apr. 15 Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer CI
Mar. 25 Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
AQ
Intellia Therapeutics : Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - Form 8-K
PU
Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer
CI
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals
MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals
MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron
DJ
Intellia Therapeutics : Termination of Material Agreement - Form 8-K
PU
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
AQ
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
CI
Transcript : Intellia Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM
North American Morning Briefing : Traders Await -2-
DJ
Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $73 From $72, Maintains Buy Rating
MT
Intellia Therapeutics Q4 Loss Widens
MT
Transcript : Intellia Therapeutics, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
AQ
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis
MT
Wolfe Research Starts Intellia Therapeutics With Peer Perform Rating
MT
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTLA Stock
  4. News Intellia Therapeutics, Inc.